Aim of the work: Is to detect the presence of anti CCP and anti CMV antibodies in rheumatological disorders other than rheumatoid arthritis and its correlation to radiological findings and disease activity. Methods: Our study was included 70 SLE patients and 30 systemic sclerosis (SSc) patients diagnosed according to ACR classification criteria. After informed consent, all patients were subjected to detailed history taking, full clinical examination including rheumatological examination, laboratory investigations: included CBC, ESR, CRP with titer, urine analysis, renal & liver function, serum uric acid, Anti CCP antibodies & Anti MCV antibodies by ELISA. X-ray and U/S on both hands and knees and disease activity score using SLEDAI score for SLE patients and SSc disease activity score (Medsgar score) for SSc patients. Results: In our study, anti CCP antibodies were found in 8 (11.4%) of SLE patients and 4 (13.3%) SSc patients, while anti MCV antibodies were found in 14 (20%) SLE patients and 8 (26.7%) of SSc patients.There is association between presence of anti CCP Abs and anti MCV Abs and a clinically evident arthritis in both SLE and SSc. Strong relationship between high CRP level and a severe arthritis and joint erosions was noticed in SLE patients. A significant radiological evident in the form of synovial hypertrophy and bony erosions were found using ultrasonography and plain X-ray with seropositive anti CCP and anti MCV Abs in both SLE and SSc patients.In our study, cut off value of anti CCP which was >12, with sensitivity of 70.42%, specificity of 60% positive predictive value of 80.6%, negative predictive value of 46.2% with diagnostic accuracy of 61.7%, and best cut off value of Anti MCV which was >11, with sensitivity of 98.46%, specificity of 30%, positive predictive value of 75.3%, negative predictive value of 90% with diagnostic accuracy of 60.2% in other rheumatological diseases other than RA. Conclusion: There is a significant association between presence of anti CCP antibodies and anti MCV antibodies and the presence of evident arthritis either clinical or radiologically by using both x-ray and U/S on both hands and knees in SLE and systemic sclerosis patients. [Egypt J Rheumatology & Clinical Immunology, 2016; 4(1): 33-41] 
INTRODUCTION
Anti-citrullinated protein antibodies (ACPA) have been reported as more specific serological markers of rheumatoid arthritis (RA). They provide a superior alternative to the rheumatoid factor (RF) test in laboratory diagnostics of RA 1 . Different studies suggest that the enzymatic citrullination and the production of ACPAs may also be associated with other inflammatory arthritis-associated autoimmune diseases 2 . In systemic lupus erythematosus (SLE) arthritis is one of the most common symptoms, seen in 60-90% of patients. In the majority of cases of SLE, arthritis is nondeforming and nonerosive and thus will not directly cause irreversible functional impairment, the presence of anti-CCP antibodies was strongly associated with erosive arthritis 3 
.
In Systemic sclerosis (SSc), polyarthritis have varied between 36-80%. Erosive arthritis have been reported throughout the metacarpophalangeal (MCP), proximal interphalangeal (PIP), and distal interphalangeal (DIP) joints, as well as the wrist. Indeed, at 7 years of SSc, bony erosions (mostly in the hands) have been noted in 4-57% of patients 4 .
Aim of the Study:
Is to detect the presence of anti CCP and anti CMV antibodies in rheumatological disorders other than rheumatoid arthritis and its correlation to radiological findings and disease activity.
PATIENTS AND METHODS

I.
Patients: This is across sectional study which included 70 patients with SLE according to ACR classification Original Article criteria 5 and 30 systemic sclerosis patients according to ACR classification criteria SSc 6 . All patients were recruited randomly by simple sampling method from rheumatology and internal medicine outpatient clinics and inpatient departments at Ain Shams University hospitals.
Ethical considerations:
The nature of the present study was explained to all participants. The laboratory and radiological procedures represent standard care and pose no ethical conflicts. Consent was obtained from all participants.
II. Methods:
All patients were subjected to detailed history taking with special emphasis on: age, sex, disease duration, drugs intake and musculoskeletal affection, full clinical examination including rheumatological examination, laboratory investigation including Erythrocyte sedimentation rate (ESR) estimation was done by the Westergren method 7 , complete blood picture: using coulter JS + cell counter) 8 , urine analysis 9 , renal functions: serum creatinine, blood urea and serum uric acid 10 , liver function: Blood proteins and serum albumin, liver enzymes: ALT and AST 11 , quantitative C-reactive protein (CRP) titer: done by immune turbidimetric method 12 , Anti CCP antibodies: quantitative measurement of IgG class autoantibodies against cyclic citrullinated peptides (CCP) in human serum or plasma by using an ELISA test system values ≥ 20 U/L considered positive 13 , Anti MCV antibodies: quantitative measurement of IgG class autoantibodies against mutated citrullinated vimentin in human serum or plasma by using ELISA test system values ≥ 20 U/L considered positive 14 .
Radiological methods:
All the patients was subjected to plain X-ray postero-anterior view for both hands and knees and numerical counting of number of erosions was done and ultrasonographic imaging of both hands and knees including assessing erosions, synovial hypertrophy and active inflammatory signs with blood flow Doppler.
Disease Activity Assessment:
• SLE disease activity was assessed by Systemic lupus erythematosus disease activity index (SLEDAI), patients with SLEDAI score less than 6 considered clinically inactive, patients with score 6-11 considered to have mild to moderate disease activity while patients with score 12 or more were considered to have severe disease activity 15 .
• SS disease activity disease severity scale for SSc recently has been developed and internally tested. The authors identified nine organ systems and identified variables for each one which could be used for defining severity 16 .
RESULTS
Demographic data of SLE patients:
The study was carried on 62 female patients and 8 male SLE patients, their age ranged from 18 to 49 years with a mean±SD 29.14±6.41 years. The disease duration ranged from 3 months to 10 years with mean±SD 2.48±2.24 years with cumulative dose of steroid in gram ranged from 1 to13 gram with mean 7.91±3.79 gram and 39 (55.71%) of patient receiving cyclophosphamide.
Demographic data of SS patients:
The study was carried on 30 female patients, their age ranged from 18 to 63 years with a mean 40.1±12.5 years. Their disease duration ranged from 2-20 years with mean 5.3±3.4 years with activity index range from 3-9 with mean±SD 5.33±1.83 with 8 (26.7%) patients received cycle of Cyclophosphamide, 30 (100%) patients on steroids and Ca channel blocker while 13 (43.3%) patients on prokinetics.
Clinical manifestations:
The most prevalent symptoms in SLE patients were nephritis as 62 (88.57%) SLE patients, 53 (75.71%) patients have malar rash, 44 (76.86%) patients have arthritis, 43 (61.4%) patients have anaemia, and 36 (51.4%) patients have photosensitivity but as regard SS, all patient had skin tightness (100%) at time of examination, 28 (93.33%) patients had Raynaud's phenomena, 11(36.7%) patients have arthritis, 10 (33.33%) patients had GIT affection, 7 (23.33%) patients had pulmonary affection, 2 (6.67%) patients had telangiectasia, calcinosis and neurological affection, 1(3.33%) patient had cardiac affection, but no patient with renal affection. Distribution of anti CCP and anti MCV among SLE patients and SSc patients; is seen in Table (1) As regard different laboratory data, there was statistical significant difference between positive anti CCP and CRP in SLE patients but there was no statistical significant difference between positive anti MCV and CRP in SLE patients. But in SSc patients, no significant difference between positive Anti CCP or Anti MCV as regard CRP.
Disease activity index in SLE (SLEDAI score) ranged from 2-28 with no statistical significant with either anti CCP and anti MCV positive and negative patients while SSc disease activity index ranged from 3-9 and it is statistically significant with anti CCP positive antibodies while highly statistical significant with anti MCV positive antibodies.
Receiver operating characteristics (ROC) curve was used to define the best cut off value of anti CCP which was >12 and cut off value of anti MCV which was >11 (Figures 1 & 2) . 
DISCUSSION
Anti-cyclic-citrullinated peptide antibodies are highly specific serological markers for RA that are thought to be directly involved in the disease pathogenesis 17 . Assays for the detection of anti-CCP antibodies have become popular in the last years for diagnosis of RA, in accordance with the 2010 RA classification criteria, ACPA detection is now used as a means of diagnosing RA 17 . Citrullinated proteins are not exclusively found in RA patients, but can also be present in patients with other inflammatory joint diseases 18 . In this study anti CCP antibodies were in 8 (11.4%) of SLE patients, while anti MCV antibodies were found in 14 (20%) SLE patients. The Anti-CCP prevalence among SLE patients in previous different studies was extremely variable. As the prevalence among different studies, ranging from 6.7 % to 37.93 % .In Romanian study was 6.7% 19 , Brazalian study was 13.7% 20 , Chinese study was 13.8% 21 , in Egyptian study was 28% 22 , in another Chinese study was 37.93% 23 . In Contrast to Damián-Abrego et al. 24 , who studied 34 SLE patients stated that SLE patients, with or without deforming arthropathy, had normal serum anti-CCP concentrations. The cause of this variability may be due to the different ethnicities, also the variability between the SLE patients in the different studies should be considered. Although Iaccarino et al. 25 estimated that the prevalence of ACPA in SLE patients with arthritis was around 57-100% and considering them as having "rhupus" (SLE-RA overlap syndrome) supporting the concept that rhupus represents the coexistence of two separated diseases in the same patient, rather than an additional disease entity.
But as regard anti MCV antibodies in SLE our results was close to the results of Egerer et al. 26 , who reported that anti-MCV antibody was detected in many rheumatic diseases and was found positive in 14% of SLE patients. Lower results were reported by Putterman et al. 27 & Poulsom and Charles 28 studies, whom studied different autoantibodies in SLE and found that 2% of his studied patients had positive anti MCV which was similar to the results of Kalunian1 et al. 29 , who studied the level of anti MCV in 210 lupus patients only found positive anti MCV in 1.9%.
As regard SSc 4 patients (13.3%) had positive anti CCP antibodies and 8 (26.7%) SSc patients had positive anti MCV antibodies. The anti-CCP prevalence among SSc patients in previous different studies was extremely variable. As the prevalence among different studies, ranging from 2.6% to 20.5%. In study done by Morita et al. 30 was 2.6%, Xia et al. Studying musculoskeletal and joint affection in SLE patients our results were agreed with Habeeb et al. 22 , who found that arthritis in the form of joint tenderness and swelling were found in 60% of the studied patients and found that anti-CCP positive patients exhibited a significant higher occurrence in comparison to negative patients as regards arthritis and Popescu et al. 19 , who found that 80% of anti CCP lupus patients had arthritis. Martinez 'study 35 had detected a similar results, in his a retrospective medical record review of a case series of five female patients with SLE and erosive arthropathy anti-CCP antibodies detected in 4 out of 5 (80%) patients, they concluded that erosive arthritis was strongly associated with the presence of anti-CCP antibodies. Also Amezcua-Guerra et al. 36 detected association of anti-CCP antibodies with erosive arthritis in SLE patients and concluded that high levels of anti-CCP may be a useful serological marker for an erosive arthritis pattern among these patients; also Tarabore et al. 37 reported that patients with SLE and positive anti-CCP antibodies have more erosive arthritis than patients without anti-CCP antibodies. Although, one study did report that even though the prevalence of anti-CCP was higher in SLE patients in comparison to control yet no relationship could be found with clinical profile including joint complaints which done by Skare et al. 20 and another study done by Galvão et al. 38 , also found no difference between the patients with or without arthritis. Studying the clinical manifestations of SLE patients with positive anti MCV antibodies had significantly more number of swollen joints, tender joints and more patients with morning stiffness than those with negative anti MCV. This is in concordance with Hussain and Jaffery 39 , who studied the association of anti-MCV autoantibodies with SLE overlapping with various syndromes and found that SLE patients with erosive arthropathy showed high level of anti-MCV autoantibodies.
Studying musculoskeletal affection among anti CCP in SSc patients; our results were close to Atzeni, et al., 40 , who showed that the frequency of arthritis was higher in patients with SSc with anti-CCP than in patients with SS without anti-CCP. On the other hand Morita et al. 30 found that SSc patients with elevated serum levels of anti-CCP antibodies exhibited arthralgias and interstitial pneumonia. In contrast to Payet et al. 30 and Gottenberg, et al. 41 , who found no significant correlation between anti CCP antibodies and any clinical symptoms Habeeb et al. 22 , who found that anti-CCP positive patients exhibited significant difference in comparison to negative patients as regards arthritis (79 vs 52%) and the presence of erosions (28 vs 5%) and presence of high CRP (78 vs 30%). As well as anti MCV positive SSc patients our results were in agreement with Xia et al. 1 , who found significant association between anti MCV antibodies with arthritis..
As regard studying laboratory findings there was statistical significant correlation between anti CCP positive SLE patients with high CRP level that was in agreement with Habeeb et al. 22 and Zhao et al. 21 , who demonstrated that anti-CCP positive patients with SLE show higher CRP and RF positivity than those with negative anti-CCP. Interestingly, since CRP does not usually increase with disease activity in SLE, in contrast to the majority of inflammatory diseases, an increase in CRP could help to distinguish SLE patients with or without classic articular involvement. This simple marker in SLE patients with articular involvement could be a warning signal of worse articular evolution. Also, that findings are supported by the results of Taraborelli et al. 37 , as they found that RF positivity and increased CRP were more frequent in erosive arthritis than in non-erosive arthritis and reported that increase in RF and CRP could be an additional means of identifying lupus patients with arthritis at risk of a worse prognosis. On the contrary Popscu et al. 19 , who found no statistical significant difference between anti CCP positive and anti CCP negative patients with CRP. Unlike SLE, among SSc patients, with positive anti CCP and anti MCV antibodies joint erosions showed no association with CRP level or other laboratory parameters as up till now no available studies in this issue.
As regard studying radiological finding of arthritis in SLE patients and the presence of anti-CCP antibodies. Previous studies have detected similar results, Another study and concluded that of anti-CCP antibodies with radiological evident joint erosions in SLE patients 60% and concluded that high levels of anti-CCP may be a useful serological marker for radiological evident of erosive arthritis pattern among these patients 36 . In addition to Zhao et al. 21 , who found that the frequency of arthritis in anti-CCP positive SLE patients (73.7%) was significantly higher than in anti-CCP negative patients (47.1%, P=0.031), they also noticed significantly higher incidence of Xray proven erosive arthritis among their anti-CCP positive SLE patients with arthritis than in anti-CCP negative patients with arthritis.
Similarly, SSc, anti CCP antibody positivity was associated with more radiological evident joint erosions that results were in agreement with Avouac et al. 42 and Atzeni, et al. 40 , whom showed that 23% of patients with SSc with positive anti CCP antibodies had radiological evidence of erosive arthritis. In contrast, Payet et al. 31 and Gottenberg, et al. 41 studies which reported that no statistical significant between SSc patients with positive anti CCP antibodies and radiological evidence of erosive arthritis. Positive anti MCV anti bodies had significantly more number of U/S and X-ray evident erosions, number of patients with synovial hypertrophy similarly Xia et al. 1 , reported that presence of anti MCV antibodies had been associated with more joint erosions in X-rays.
As regard Sensitivity and specificity of Anti-CCP antibodies which is an antibody directed against a variety of citrullinated proteins, has been considered a useful tool in RA diagnosis and prognosis. Among the different autoantibodies described in RA patients, anti-CCP displays the strongest specificity (95-98%) with 70-80% sensitivity 43 . Variable results were found in another studies Budhram, et al. 44 found that SLE sensitivity of anti CCP antibodies was 47.8% while specificity was 91.8%. Also Díaz-Toscano et al. 45 studied anti-CCP antibodies and anti-MCV antibodies in RA in relation to other chronic inflammatory rheumatic diseases mainly SLE and SSc and reported that sensitivity 85% (78-90), specificity 92% (84-97), positive predictive value 94% (89-98) and negative predictive value 79% (70-86), While Morita et al. 29 , who studied SS -RA overlap for anti CCP sensitivity (86%), specificity (97%), PPV (67%) and NPV (99%).
Conclusion
There is a significant association between presence of anti CCP antibodies and anti MCV antibodies and the presence of evident arthritis either clinical or radiologically by using both x-ray and U/S in SLE and systemic sclerosis patients.
